FLSM
SLN

Frazier Life Sciences Management’s Silence Therapeutics SLN Stock Holding History

Frazier Life Sciences Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-970,130
Closed -$5.03M – 51
2025
Q3 		$5.03M Hold
970,130
– – 0.15% 45
2025
Q2 		$5.63M Sell
970,130
-178,461
-16% -$765K 0.23% 44
2025
Q1 		$3.24M Hold
1,148,591
– – 0.15% 46
2024
Q4 		$7.9M Hold
1,148,591
– – 0.33% 39
2024
Q3 		$20.9M Hold
1,148,591
– – 0.84% 27
2024
Q2 		$21.8M Hold
1,148,591
– – 1.02% 27
2024
Q1 		$24.8M Buy
1,148,591
+267,418
+30% +$5.81M 1.05% 28
2023
Q4 		$15.3M Hold
881,173
– – 0.82% 34
2023
Q3 		$8.66M Hold
881,173
– – 0.58% 33
2023
Q2 		$4.85M Hold
881,173
– – 0.29% 42
2023
Q1 		$5.46M Hold
881,173
– – 0.4% 41
2022
Q4 		$13.4M Hold
881,173
– – 0.84% 24
2022
Q3 		$8.7M Hold
881,173
– – 0.67% 32
2022
Q2 		$10.4M Hold
881,173
– – 0.99% 28
2022
Q1 		$16.7M Buy
+881,173
New +$17.6M 1.43% 22

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Frazier Life Sciences Management's SLN Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 970,130 shares — an estimated $5.03M sold.

Frazier Life Sciences Management first reported a position in SLN in Q1 2022 and held it in 15 quarters. The position peaked at $24.8M in Q1 2024. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Frazier Life Sciences Management reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 970,130 Silence Therapeutics shares in Q4 2025, an estimated $5.03M.
  • Frazier Life Sciences Management first reported a position in Silence Therapeutics in Q1 2022 and held it in 15 quarters.
  • Frazier Life Sciences Management's Silence Therapeutics position peaked at $24.8M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.